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Summan- Chemotherapy with the cytotoxic drug procarbazine (PCB) causes permanent infertility in most
male patients. Since many patients treated with this cytotoxic drug are of reproductive age it is important to
develop a method to protect spermatogenesis and fertility. It has been hypothesised that 'spermatogenic arrest'
by pharmacological intervention may render the testes less susceptible to the effects of chemotherapy. The
present study investigated whether recovery of fertility in a male rat model could be achieved by suppression
of spermatogenesis with high doses of clomiphene citrate (CC) prior to PCB administration. It was demon-
strated that young male rats treated with a combination of CC and PCB partially recovered spermatogenesis
and achieved almost normal fertility. In contrast, animals treated with PCB alone exhibited abnormal
spermatogenesis and remained infertile.
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The increasing success of chemotherapy in prolongation of
life of patients with various malignant and non-malignant
diseases has called attention to late effects of cytotoxic treat-
ment. including permanent sterility. For example, more than
80% of male patients treated with MOPP combination for
Hodgkin's disease become either azoospermic or severely
oligospermic (Whitehead et al., 1982). Similar disorders have
been noted to affect long-term survivors of acute leukaemia,
testicular cancer. non-Hodgkin's lymphoma and collagen vas-
cular diseases treated with cytotoxic drugs (Pennisi et al..
1975: Schilsky et al., 1980: Drasga et al., 1983). The main
drugs that cause infertility are alkylating agents (Fairley et
al.. 1972). including nitrosoureas and procarbazine (PCB),
however vinblastine and cisplatinum have also been impli-
cated (Roeser et al.. 1978: Morris and Shalet, 1990). Since
many patients are of reproductive age. it would be of impor-
tance to develop a method enabling some protection of sper-
matogenesis and fertility.
It has been suggested that 'spermatogenic arrest' caused by
drug-induced blockage of the pituitary gonadal axis protects
the testis from the effects of chemotherapy (Glode et al..
1981). It is well known that cytotoxic drugs affect mainly
actively dividing cells, which in the testis are spermatogonia.
However. 'spermatogenic arrest' does not completely stop
mitosis in spermatogonia either following hypophysectomy
(Clermont and Harvey. 1967) or as a result of drug-induced
blockage of gonadotropin secretion. Thus, the mechanism by
which the 'spermatogenic arrest' reduces testicular damage is
still unclear.
Several authors have tried to protect the testis from
chemotherapy by using different drugs. Gonadotropin-
releasing hormone agonists have been shown to protect sper-
matogenesis in PCB-treated animals (Nseyo et al., 1985;
Ward et al., 1990), but not in humans (Johnson et al., 1985;
Waxman, 1987: Kreuser and Hetzel, 1988). In addition to
work on features of testicular histology as criteria for
gonadal protection, there are reports concerning the effect of
PCB on other testicular parameters, such as testosterone and
androgen-binding protein levels (Morris et al., 1990), and on
reproductive function following chemotherapy or scrotal
irradiation (Velez de la Calle and Jegou, 1990; Jegou et al..
1991).
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In view of the limited success of all attempts reported to
date, we looked for another agent capable of producing
rapid, complete and reversible spermatogenic arrest. Clomi-
phene citrate (CC), a synthetic oestrogen agonist-antagonist,
in high doses reversibly decreases sperm concentration in
men (Heller et al., 1969). Recently. it was shown that in male
rats high doses of CC administered daily for a 3 week penrod
caused temporary reversible spermatogenic arrest chiefly at
the meiotic stage (Weissenberg et al.. 1992). although a few
round spermatids were still apparent.
In the present study we demonstrate that high doses of CC
may protect spermatogenesis in PCB-treated male rats, re-
sulting in an almost normal fertility potential.
Metbods
Four groups of locally bred Wistar male rats aged 25 days
and weighing 55-60 g were treated as follows: Group 1 (17
rats) received CC (Sigma) 0.25 mg day-' in 0.2 ml of 20%
ethanol saline by daily subcutaneous injections over 4 or 8
weeks. Group 2 (14 rats) did not receive any treatment for 4
weeks and were injected (i.p.) with PCB (kindly supplied by
Hoffman-LaRoche) once weekly throughout weeks 5-8. The
first dose of PCB was administered at the age of 53 days and
was 150 mgkg'- followed by 3 weekly doses of 100 mg kg-'.
Group 3 (14 rats) received CC as in group I for 8 weeks.
Throughout weeks 5-8 PCB was added, as in group 2.
Group 4 (14 rats) received the vehicle only.
After 4 weeks of treatment with CC, three animals from
group 1 were sacrificed and their testes were removed,
weighed and processed for histological studies. At the end of
the entire 8 week treatment period, four animals from each
group were sacrificed and their testes were evaluated as
above. The remaining animals were allowed to recover. Eight
weeks following the recovery period mating experiments were
carried out. Each male was caged with two proven fertile
females during four consecutive oestrous cycles. The females
were then removed and replaced with two other females,
which were left with the males for the same penrod of time.
Pregnancy, birth and the number of pups per litter were
recorded. At the end of the recovery period (i.e. about 13
weeks) the animals were sacrificed and the testes were
removed, weighed and processed for histological studies.
Paraffin sections were-stained with haematoxylin and eosin
and photographed on an Olympus microscope.The number of tubules exhibiting spermatogenesis in each
cross-section was calculated and expressed as a percentage of
the total seiniferous tubules counted in the section.
In order to examine whether CC may interfere with the
cytotoxic effects of PCB, white blood cell differential count
was performed on the PCB + CC-treated rats (group 3) and
compared with that in rats treated with PCB only. Blood
samples were colleted from four rats prior to PCB admini-
stration and 10 days after cessation of PCB + CC treatment,
and total granulocyte count was determined.
For estmation of treatment effects on testes weight and on
testicular histology within each test group, one-way analysis
of variane was applied. Subsequently, differences between
control and treated groups were examined by Student t-test
For estimation of treatment effects on fertilty Fisher's exact
probability test was appLied.
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All animals survived until the end of the study, and no
signficant complications resulting from the various
treatments were observed.
CC inhibited an increase in testicular weight following 8
weeks of daily adminstration. However, at the end of the
recovery period the testis weight of the CC-treated group
reached control values (Table I, group 1). Treatment with
PCB alone inhibited testicular weight increase at the end of
treatment. This inhibition was even more prominent at the
end ofthe recovery peiod (Table I, group 2). Rats pretreated
with CC and then given PCB exhibited a precipitous decrease
in testicular weight at the end ofthe treatment period. In this
group there was an increase in testicular weight foLowing the
recovery period, but it did not reach control levels (Table I,
group 3). There was no remarkable difference in body weight
between the various groups at the end of the recovery period.
Testicular histology
CC caused an arrest in spermatogenesis mainly at the stage
of primary spermatocytes. This effect was noted after 4 weeks
of treatment and emained constant after 8 weeks (Figure 1).
However, mitosis of spermatogonia was observed even under
CC treatment in spite of 'spermatogenic arrest'. Comparative
quantitative analysis of mitosis of spermatogonia under the
various treatments was not performed. After the recovery
period, spermatogeness was renewed and appeared normal
in 100% of seminiferous tubules of rats in group I (Figure
2). In the rats treated with PCB only there was a difference
between the effect of PCB at the termination of treatment as
compared with that observed following recovery period. At
the end of treatment, the majority of the tubules contained
degenerated serpmatozoa formed before PCB administration,
with shrunken germinal cells attached to the seminiferous
tubule basal membrane. Further degeneration ofseminiferous
tubules was noted in this group following the recovery penod
(Figure 3). Regeneration of the germinal cells was observed
in 0-2% of the seminiferous tubules. The testes of rats
pretreated with CC and then given PCB (group 3) were
charactensed by loss of germinal epithelium in some of the
seminiferous tubules and by spermatogenic arrest at the stage
of prmary spermatocytes in others at the end of treatment.
However, at the end of recovery period, the histology of the
Fgw I Rat testis folowing 8 weeks of treatment with CC; the
seminiferous tubules contain cells up to prmary spermatocytes
and occasional round spermatids.
AV
Fwe 2 Rat testis following 8 weeks of treatment with CC and
13 weeks of recovery period; virtually complete spermatogenesis
can be observed
Figwe 3 Rat testis after treatment with PCB, at the end of the
recovery period; most of the seminiferous tubules are devoid of
grminal elments.
Table I Paired testes weight at the end of treatment and at the end of the recovery
perod
Group 1 Group 2 Group 3 Group 4
CC PCB CC + PCB Control
At termination of 1.57±0.02* 1.36±0.01* 0.6±0.01* 2.57±0.02
treatment
At end of recovery 2.%±0.098 0.77±0.069*** 1.75±0.056* 2.%±0.12
period
*P<0.01 vs controls. **P<0.01 vs group 3. All results are means±s.d.a..dh dki.- reues ymaii C__db-lo i--ces pffbahmA '111M CM " sn r t _e1
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testes revealed virtually complete regeneration of sper-
matogenesis in the preserved tubules and lack of regeneration
in tubules devoid of germinal epithelium (Figure 4). The
percentage of preserved seminiferous tubules varied among
experimental animals with a mean of 51.7%± 21.7% and a
median of 52%. The difference in regeneration between the
rats treated with PCB only and the CC + PCB-treated rats
was statisically significant (P<O.001).
Table H demonstrates the fertility of the various groups
during the recovery period. This was expressed as the percen-
tage of male rats which were able to impregnate females and
the number of offspring per litter. CC-treated rats regained
normal fertility, whereas PCB-treated rats remained sterile.
Rats pretreated with CC and then given PCB gradually
regained their fertility. The offspring were of normal birth
weight and development at 6 weeks follow-up. Clomiphene
did not interfere with the cytotoxic effect of PCB. The
granulocyte counts in CC + PCB-treated animals decreased
from 11 ±3 x1091-' before the administration of PCB to
3 ± 1.2 x 1091-' 10 days after the end of treatment. This
decrease was statistically significnt (P<0.001). The decrease
in granulocyte count in rats treated with PCB only was
similar- from 11.5 ±2 x 109 11 before the administration of
Fugwe 4 Rat testis after combined treatment with CC and PCB,
and followig the recovery perod. Loss of germnal epithelium is
observed in some of the seminiferous tubules, while complete
spermatogenesis is seen in the preserved tubules.
PCB to 3.5 ± 1 x 109 1- 10 days after the treatment. These
results show that co-administration of CC does not interfere
with the cytotoxic effect of PCB.
Recent advances in chemotherapy and radiation therapy
have significantly increased the life expectancy of patients
with various malignant and non-malignant disorders. How-
ever, the occurrence of long-term side-effects, notably
sterility, has become an important factor, especially in young
patients. Various cytotoxic drugs cause gonadal damage and
sterility. The MOPP regimen, commonly employed for treat-
ment of Hodgkin's disease, causes irreversible sterility in men
of reproductive age (Schilsky et al., 1980). This effect is the
result mainly of the PCB included in the drug combination.
Treatment which would prevent or decrease the damage to
germinal epithelium could significantly improve the quality of
life of many patients.
This study presents the first evidence that the induction of
spermatogenic arrest with the ministration of CC may
preserve a high percentage of wminiferous tubules, eventually
sustaining both spermatogenesis and reproductive function in
PCB-treated rats.
In the present study we demonstrated that administration
of CC may maintain spermatogenesis and reproductive
potential in a PCB-treated rat model without signifcnt side-
effects. Moreover, although only a part of the seminiferous
tubules exhibited active spermatogenesis after recovery from
PCB treatment, the reproductive ability is nonetheless pre-
served. The evaluation of the clinical value of CC use in
humans must consider and define the shortest period of
pretreatment with CC before initiation of chemotherapy, as
cytotoxic treatment cannot be withheld in order to achieve
maximal spermatogenic arrest. These studies are currently
being undertaken by our group. Since high doses of CC have
been shown to cause azoospermia without significant side-
effects in men (Heller et al., 1969), further research should
establish the relevance of this model to man, as differences
between the response to CC of rat and man regarding its
effect on gonadotropin secretion might be expected. Clomi-
phene citrate, an oestrogen agonist-antagonist, is clnically
employed for induction of ovulation and has been extensively
studied for its effect on reproductive function in humans and
in rats. In relatively high doses, CC has been shown to
reversibly suppress gonadotropin secretion, decrease testo-
sterone levels and cause spermatogenic arrest (Heller et al.,
1969; Weissenberg et al., 1992). However, a direct effect of
CC on the testis could not be excluded. As shown in our
study, this suppression is entirely reversible upon cessation of
administration of the drug.
Releasing hormone agonists and gonadal steroid hormones
have been evaluated for their capacity to prevent testicular
damag caused by cytotoxic drugs. Treatment of mice, rats
and baboons with luteinising hormone-relaing hormone
(LH-RH) agonists have been reported to confer various
degrees of testicular preservation (Glode et al., 1981; Lewis et
al., 1985; Ward et al., 1990) notwithstanding contrary views
expressed on lack of grminal epithelium protection (da
Cunha et al., 1987; Karashima et al., 1988; Papadopoulos,
1991). Several of these studies pointed to suppression of
Table H Fertilising ability of male rats following administration of PCB or combined treat-
ment
Group I Group 2 Group 3 Group 4
CC PCB CC + PCB Control
Mating I II I II I II I II
Fertile(%) 100 100 0 0 60 80 100 100
(10/10) (10/10) (0/10) (0/10) (6/10)* (8/10)* (10/10) (10/10)
Size oflitter 8 11 - 8 10 10 11
(range) (7-10) (10-12) (1-11) (6-12) (8-12) (9-12)
*P<0.01 vs PCB.
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spermatogenesis and prevention of testicular damage in rats
undergoing chemotherapy. Moreover, LH-RH analogue fail-
ed to protect fertility in men treated with the MOPP regimen
for Hodgkin's disease (Johnson et al., 1985; Waxman, 1987).
Testosterone was found to protect approximately 22% of
seminiferous tubules from damage by PCB in rats (Delic et
al., 1986). Oestrogen alone, however, failed to shield the
germinal epithelium (Morris and Ward, 1989), but addition
of oestradiol to testosterone was found to enhance protection
(Parchuri et al., 1993; Meistrich et al., 1994).
Clomiphene might have a direct oestrogenic effect on the
testes and therefore acts as androgen antagonist. Direct
effects on testicular RNA and protein synthesis have already
been demonstrated (Hollinger 1970, 1971; Hollinger and
Hwang, 1972). Flickinger (1977) reported alteration of
clomiphene on the male reproductive tract similar to those
seen following oestrogen treatment. Oestradiol treatment of
young rats during 3 weeks caused 'spermatogenic arrest'
similar to that observed under clomiphene treatment (R
Weissenberg, personal data). Yet, use of oestrogen alone or
clomiphene for protection of testis from damage induced by
PCB led to contradictory results, for reasons which are not
apparent.
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